Soni Bhavnita, Kabra Ritika, Singh Shailza
National Centre for Cell Science, Pune, India.
J Interferon Cytokine Res. 2021 Jul;41(7):244-257. doi: 10.1089/jir.2020.0156.
Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV-2), which initiated as an endemic from China, converted into a pandemic disease worldwide within a couple of months' time. This has led researchers from all over the world to come together to find and develop possible curative or preventive strategies, including vaccine development, drug repurposing, plasma therapy, drug discovery, and cytokine-based therapies. Herein, we are providing, a summarized overview of immunopathology of the SARS-CoV-2 along with various therapeutic strategies undertaken to COVID-19 with a vision for their possible outcome. High levels of proinflammatory cytokines such as interleukin (IL)-7, G-CSF, IP-10, TNF-α, monocyte chemoattractant protein-1 (MCP-1), and IL-2 in severe cases of COVID-19 have been observed. Immune responses play significant roles in the determination of SARS-CoV-2 pathogenesis. Thus, exploring the underlying mechanism of the immune system response to SARS-CoV-2 infection would help in the prediction of disease course and selection of intensive care and therapeutic strategy. As an effort toward developing possible therapeutics for COVID-19, we highlighted different types of vaccines, which are under clinical trials, and also discussed the impact of genome variability on efficacy of vaccine under development.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)最初在中国呈地方性流行,在短短几个月内就演变成全球大流行病。这促使世界各地的研究人员齐聚一堂,寻找并开发可能的治疗或预防策略,包括疫苗研发、药物重新利用、血浆疗法、药物发现以及基于细胞因子的疗法。在此,我们提供SARS-CoV-2免疫病理学的简要概述,以及针对COVID-19采取的各种治疗策略,并展望其可能的结果。在COVID-19重症病例中,已观察到高水平的促炎细胞因子,如白细胞介素(IL)-7、粒细胞集落刺激因子(G-CSF)、干扰素诱导蛋白10(IP-10)、肿瘤坏死因子-α(TNF-α)、单核细胞趋化蛋白1(MCP-1)和IL-2。免疫反应在SARS-CoV-2发病机制的确定中起着重要作用。因此,探索免疫系统对SARS-CoV-2感染反应的潜在机制将有助于预测疾病进程以及选择重症监护和治疗策略。作为开发COVID-19可能治疗方法的一项努力,我们重点介绍了正在进行临床试验的不同类型疫苗,并讨论了基因组变异性对正在研发疫苗疗效的影响。